Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

References

• Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin. Cancer Res.14(24), 8019–8026 (2008).
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin. Chem.54(11), 1770–1779 (2008).
   PubMed Web of Science ®Google Scholar
• Schmitt M, Lazar V. Disease-related forecast cancer biomarkers, a topic in focus of the new international Cancer Research consortium worldwide innovative network in personalized cancer medicine (win). Bioanalysis2(5), 851–853 (2010).
   PubMedGoogle Scholar
• Ejlertsen B, Jensen MB, Nielsen KV et al. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J. Clin. Oncol.28(6), 984–990 (2010).
   PubMed Web of Science ®Google Scholar
• van’t Veer LJ, Paik S, Hayes DF. Gene expression profiling of breast cancer: a new tumor marker. J. Clin. Oncol.23(8), 1631–1635 (2005).
   PubMed Web of Science ®Google Scholar
• Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol.11(1), 55–65 (2010).
   PubMed Web of Science ®Google Scholar
• Rauser S, Marquardt C, Balluff B et al. Classification of HER2 receptor status in breast cancer tissues by maldi imaging mass spectrometry. J. Proteome Res.9(4), 1854–1863 (2010).
   PubMed Web of Science ®Google Scholar
• Napieralski R, Brünner N, Mengele K, Schmitt M. Emerging biomarkers in breast cancer care. Biomarkers Med.4(4), 505–522 (2010).
   PubMedGoogle Scholar
• Schrohl AS, Holten-Andersen M, Sweep F et al. Tumor markers: from laboratory to clinical utility. Mol. Cell. Proteomics2, 378–387 (2003).
   PubMed Web of Science ®Google Scholar
• Rodriguez H, Tezak Z, Mesri M et al. Analytical validation of protein-based multiplex assays: a workshop report by the NCI–FDA interagency oncology task force on molecular diagnostics. Clin. Chem.56(2), 237–243 (2010).
   PubMed Web of Science ®Google Scholar
• Lea P, Ling M. New molecular assays for cancer diagnosis and targeted therapy. Curr. Opin. Mol. Ther.10(3), 251–259 (2008).
   PubMedGoogle Scholar
• Smith MQ, Staley CA, Kooby DA et al. Multiplexed fluorescence imaging of tumor biomarkers in gene expression and protein levels for personalized and predictive medicine. Curr. Mol. Med.9(8), 1017–1023 (2009).
   PubMed Web of Science ®Google Scholar
• Martinkova J, Gadher SJ, Hajduch M et al. Challenges in cancer research and multifaceted approaches for cancer biomarker quest. FEBS Lett.583(11), 1772–1784 (2009).
   PubMedGoogle Scholar
• Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med.360(8), 790–800 (2009).
   PubMed Web of Science ®Google Scholar
• Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol.25(33), 5287–5312 (2007).
   PubMed Web of Science ®Google Scholar
• Harbeck N, Salem M, Nitz U, Gluz O, Liedtke C. Personalized treatment of breast cancer: present concepts and future directions in early stage disease. Cancer Treat. Rev. (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat. Rev. Cancer7(7), 545–553 (2007).
   PubMed Web of Science ®Google Scholar
• Hinestrosa MC, Dickersin K, Klein P et al. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat. Rev. Cancer7(4), 309–315 (2007).
   PubMedGoogle Scholar
• Harbeck N, Schmitt M, Paepke S, Allgayer H, Kates RE. Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms. Crit. Rev. Clin. Lab. Sci.44(2), 179–201 (2007).
   PubMed Web of Science ®Google Scholar
• Sturgeon CM, Duffy MJ, Stenman UH et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin. Chem.54(12), e11–79 (2008).
   PubMed Web of Science ®Google Scholar
• O’Grady P, Lijnen HR, Duffy MJ. Multiple forms of plasminogen activator in human breast tumors. Cancer Res.45(12 Pt 1), 6216–6218 (1985).
   PubMed Web of Science ®Google Scholar
• Duffy MJ, O’Grady P, Devaney D, O’Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer62(3), 531–533 (1988).
   PubMed Web of Science ®Google Scholar
• Janicke F, Schmitt M, Ulm K, Gossner W, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet2(8670), 1049 (1989).
   Google Scholar
• Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin. Thromb. Hemost.17(3), 303–312 (1991).
   PubMed Web of Science ®Google Scholar
• Schmitt M, Harbeck N, Thomssen C et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost.78(1), 285–296 (1997).
   PubMed Web of Science ®Google Scholar
• Schmitt M, Mengele K, Gkazepis A et al. Assessment of uPA (urokinase-type plasminogen activator) and its inhibitor PAI-1 in breast cancer tissue. Historical aspects and future prospects. Breast Care3(Suppl. 2), 3–10 (2008).
   PubMed Web of Science ®Google Scholar
• Janicke F, Prechtl A, Thomssen C et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl Cancer Inst.93(12), 913–920 (2001).
   PubMed Web of Science ®Google Scholar
• Look MP, van Putten Wl, Duffy MJ et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl Cancer Inst.94(2), 116–128 (2002).
   PubMed Web of Science ®Google Scholar
• Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl Cancer Inst.88(20), 1456–1466 (1996).
   PubMed Web of Science ®Google Scholar
• Grebenchtchikov N, Maguire TM, Riisbro R et al. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol. Rep.14(1), 235–239 (2005).
   PubMed Web of Science ®Google Scholar
• Wang L, Madigan MC, Chen H et al. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol. Oncol.114(2), 265–272 (2009).
   PubMedGoogle Scholar
• Chen H, Hao J, Wang L, Li Y. Coexpression of invasive markers (uPA, cd44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br. J. Cancer101(3), 432–440 (2009).
   PubMedGoogle Scholar
• Chambers SK, Gertz RE Jr, Ivins CM, Kacinski BM. The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer75(7), 1627–1633 (1995).
   PubMed Web of Science ®Google Scholar
• Scott-Coombes DM, Whawell SA, Vipond MN, Crnojevic L, Thompson JN. Fibrinolytic activity of ascites caused by alcoholic cirrhosis and peritoneal malignancy. Gut34(8), 1120–1122 (1993).
   PubMed Web of Science ®Google Scholar
• Huber K, Wojta J, Kirchheimer JC, Ermler D, Binder BR. Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid. Eur. J. Clin. Invest.18(6), 595–599 (1988).
   PubMed Web of Science ®Google Scholar
• Boss EA, Massuger LF, Thomas CM et al. Clinical value of components of the plasminogen activation system in ovarian cyst fluid. Anticancer Res.22(1A), 275–282 (2002).
   PubMed Web of Science ®Google Scholar
• Konecny G, Untch M, Pihan A et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin. Cancer Res.7(6), 1743–1749 (2001).
   PubMed Web of Science ®Google Scholar
• Hoffmann G, Pollow K, Weikel W et al. Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters. Clin. Chem. Lab. Med.37(1), 47–54 (1999).
   PubMedGoogle Scholar
• Gleeson NC, Hill Bj, Moscinski LC et al. Urokinase plasminogen activator in ovarian cancer. Eur. J. Gynecol. Oncol.17(2), 110–113 (1996).
   PubMedGoogle Scholar
• Kuhn W, Pache L, Schmalfeldt B et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol.55(3 Pt 1), 401–409 (1994).
   PubMed Web of Science ®Google Scholar
• Cai Z, Li YF, Liu FY, Feng YL, Hou JH, Zhao MQ. Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer. Ai Zheng26(3), 312–317 (2007).
   PubMedGoogle Scholar
• Ljuca D, Fatusic Z, Iljazovic E, Ahmetovic B. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage. Bosn. J. Basic Med. Sci.7(2), 111–116 (2007).
   PubMedGoogle Scholar
• Borgfeldt C, Bendahl PO, Gustavsson B et al. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer. Int. J. Cancer107(4), 658–665 (2003).
   PubMedGoogle Scholar
• Koensgen D, Mustea A, Denkert C, Sun PM, Lichtenegger W, Sehouli J. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer. Anticancer Res.26(2C), 1683–1689 (2006).
   PubMedGoogle Scholar
• Ho Ch, Yuan CC, Liu SM. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer. Gynecol. Oncol.75(3), 397–400 (1999).
   PubMedGoogle Scholar
• Schmalfeldt B, Kuhn W, Reuning U et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res.55(18), 3958–3963 (1995).
   PubMed Web of Science ®Google Scholar
• Abendstein B, Daxenbichler G, Windbichler G et al. Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. Anticancer Res.20(1B), 569–572 (2000).
   PubMedGoogle Scholar
• van der Burg ME, Henzen-Logmans SC, Berns EM, Van Putten WL, Klijn JG, Foekens JA. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors. Int. J. Cancer69(6), 475–479 (1996).
   PubMed Web of Science ®Google Scholar
• Chambers SK, Ivins CM, Carcangiu Ml. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int. J. Cancer79(5), 449–454 (1998).
   PubMedGoogle Scholar
• Tecimer C, Doering Dl, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL. Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. Int. J. Gynecol. Cancer10(5), 372–381 (2000).
   PubMedGoogle Scholar
• Kuhn W, Schmalfeldt B, Reuning U et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br. J. Cancer79(11–12), 1746–1751 (1999).
   PubMedGoogle Scholar
• Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. Gynecol. Oncol.80(1), 48–55 (2001).
   PubMedGoogle Scholar
• Steiner E, Pollow K, Hasenclever D et al. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer. Gynecol. Oncol.108(3), 569–576 (2008).
   PubMedGoogle Scholar
• Fredstorp-Lidebring M, Bendahl PO, Brunner N et al. Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer. Eur. J. Cancer37(18), 2339–2348 (2001).
   PubMedGoogle Scholar
• Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res.54(24), 6539–6548 (1994).
   PubMed Web of Science ®Google Scholar
• Horn LC, Pippig S, Raptis G et al. Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix. Aust. NZ J. Obstet. Gynaecol.42(4), 383–386 (2002).
   PubMedGoogle Scholar
• Hazelbag S, Kenter GG, Gorter A, Fleuren GJ. Prognostic relevance of TGF-β1 and PAI-1 in cervical cancer. Int. J. Cancer112(6), 1020–1028 (2004).
   PubMed Web of Science ®Google Scholar
• Cozzi PJ, Wang J, Delprado W et al. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum. Pathol.37(11), 1442–1451 (2006).
   PubMedGoogle Scholar
• Kumano M, Miyake H, Muramaki M, Furukawa J, Takenaka A, Fujisawa M. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol. Oncol.27(2), 180–186 (2009).
   PubMedGoogle Scholar
• Ohta S, Fuse H, Fujiuchi Y, Nagakawa O, Furuya Y. Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer. Anticancer Res.23(3C), 2945–2950 (2003).
   PubMedGoogle Scholar
• Gupta A, Lotan Y, Ashfaq R et al. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur. Urol.55(5), 1124–1133 (2009).
   PubMedGoogle Scholar
• Shariat SF, Roehrborn CG, Mcconnell JD et al. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J. Clin. Oncol.25(4), 349–355 (2007).
   PubMed Web of Science ®Google Scholar
• Usher PA, Thomsen OF, Iversen P et al. Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int. J. Cancer113(6), 870–880 (2005).
   PubMedGoogle Scholar
• Riddick AC, Shukla CJ, Pennington CJ et al. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br. J. Cancer92(12), 2171–2180 (2005).
   PubMedGoogle Scholar
• Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer78(3), 487–492 (1996).
   PubMedGoogle Scholar
• Hofmann R, Lehmer A, Hartung R, Robrecht C, Buresch M, Grothe F. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J. Urol.155(3), 858–862 (1996).
   PubMedGoogle Scholar
• Bhuvarahamurthy V, Schroeder J, Kristiansen G et al. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma. Oncol. Rep.14(3), 777–782 (2005).
   PubMedGoogle Scholar
• Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J. Urol.174(2), 461–465 (2005).
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Kawai T, Torikata C, Aurues T, Ikeda T. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma. Cancer82(4), 724–732 (1998).
   PubMedGoogle Scholar
• Span PN, Witjes JA, Grebenchtchikov N et al. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. BJU Int.102(2), 177–182 (2008).
   PubMedGoogle Scholar
• Hasui Y, Marutsuka K, Asada Y, Osada Y. Prognostic value of urokinase-type plasminogen activator in patients with superficial bladder cancer. Urology47(1), 34–37 (1996).
   PubMed Web of Science ®Google Scholar
• Seddighzadeh M, Steineck G, Larsson P et al. Expression of uPA and uPAR is associated with the clinical course of urinary bladder neoplasms. Int. J. Cancer99(5), 721–726 (2002).
   PubMed Web of Science ®Google Scholar
• El-Kott AF, Khalil AM, El-Kenawy Ael M. Immunohistochemical expressions of uPA and its receptor uPAR and their prognostic significant in urinary bladder carcinoma. Int. Urol. Nephrol.36(3), 417–423 (2004).
   PubMedGoogle Scholar
• Shariat SF, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology61(5), 1053–1058 (2003).
   PubMed Web of Science ®Google Scholar
• Skelly MM, Troy A, Duffy MJ et al. Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin. Cancer Res.3(10), 1837–1840 (1997).
   PubMed Web of Science ®Google Scholar
• Ganesh S, Sier CF, Heerding MM et al. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes’ stage b and c colorectal cancer. Br. J. Cancer75(12), 1793–1801 (1997).
   PubMed Web of Science ®Google Scholar
• Herszenyi L, Plebani M, Carraro P et al. The role of cysteine and serine proteases in colorectal carcinoma. Cancer86(7), 1135–1142 (1999).
   PubMed Web of Science ®Google Scholar
• Papadopoulou S, Scorilas A, Yotis J et al. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. Tumour Biol.23(3), 170–178 (2002).
   PubMedGoogle Scholar
• Seetoo DQ, Crowe PJ, Russell PJ, Yang JL. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J. Surg. Oncol.82(3), 184–193 (2003).
   PubMedGoogle Scholar
• Zlobec I, Minoo P, Baumhoer D et al. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer112(3), 495–502 (2008).
   PubMedGoogle Scholar
• Minoo P, Baker K, Baumhoer D, Terracciano L, Lugli A, Zlobec I. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer. Hum. Pathol.41(1), 70–78 (2010).
   PubMedGoogle Scholar
• Inuzuka K, Ogata Y, Nagase H, Shirouzu K. Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma. J. Surg. Res.93(2), 211–218 (2000).
   PubMed Web of Science ®Google Scholar
• Langenskiold M, Holmdahl L, Angenete E, Falk P, Nordgren S, Ivarsson ML. Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer. Tumour Biol.30(4), 210–220 (2009).
   PubMedGoogle Scholar
• Angenete E, Langenskiold M, Palmgren I et al. uPA and PAI-1 in rectal cancer – relationship to radiotherapy and clinical outcome. J. Surg. Res.153(1), 46–53 (2009).
   PubMed Web of Science ®Google Scholar
• Smolarz B, Romanowicz-Makowska H, Kulig A. Plasminogen activator inhibitor 1 (PAI-1) 1334G/A genetic polymorphism in colorectal cancer. Acta. Biochim. Pol.50(2), 489–495 (2003).
   PubMedGoogle Scholar
• Loktionov A, Watson MA, Stebbings WS, Speakman CT, Bingham SA. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Lett.189(2), 189–196 (2003).
   PubMed Web of Science ®Google Scholar
• Forsti A, Lei H, Tavelin B et al. Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer. Ann. Oncol.18(12), 1990–1994 (2007).
   PubMedGoogle Scholar
• Smolarz B, Blasiak J, Kulig A et al. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer. J. Exp. Clin. Cancer Res.20(2), 247–252 (2001).
   PubMedGoogle Scholar
• Nekarda H, Schmitt M, Ulm K et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res.54(11), 2900–2907 (1994).
   PubMed Web of Science ®Google Scholar
• Kaneko T, Konno H, Baba M, Tanaka T, Nakamura S. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci.94(1), 43–49 (2003).
   PubMed Web of Science ®Google Scholar
• Luebke T, Baldus SE, Spieker D et al. Is the urokinase-type plasminogen activator system a reliable prognostic factor in gastric cancer? Int. J. Biol. Markers21(3), 162–169 (2006).
   PubMedGoogle Scholar
• Beyer BC, Heiss MM, Simon EH et al. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer106(5), 1026–1035 (2006).
   PubMedGoogle Scholar
• Heiss MM, Babic R, Allgayer H et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. Clin. Oncol.13(8), 2084–2093 (1995).
   PubMedGoogle Scholar
• Plebani M, Herszenyi L, Carraro P et al. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin. Exp. Metastasis15(4), 418–425 (1997).
   PubMedGoogle Scholar
• Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbb-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J. Clin. Oncol.18(11), 2201–2209 (2000).
   PubMed Web of Science ®Google Scholar
• Heiss MM, Babic R, Allgayer H et al. The prognostic impact of the urokinase-type plasminogen activator system is associated with tumour differentiation in gastric cancer. Eur. J. Surg. Oncol.22(1), 74–77 (1996).
   PubMedGoogle Scholar
• Cho JY, Chung HC, Noh SH, Roh JK, Min JS, Kim BS. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer79(5), 878–883 (1997).
   PubMed Web of Science ®Google Scholar
• Sakakibara T, Hibi K, Koike M et al. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer. Cancer Sci.97(5), 395–399 (2006).
   PubMedGoogle Scholar
• Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer. Br. J. Surg.84(12), 1651–1664 (1997).
   PubMedGoogle Scholar
• Nekarda H, Schlegel P, Schmitt M et al. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin. Cancer Res.4(7), 1755–1763 (1998).
   PubMedGoogle Scholar
• Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am. J. Pathol.156(2), 567–575 (2000).
   PubMedGoogle Scholar
• Goscinski MA, Suo Z, Florenes VA, Vlatkovic L, Nesland JM, Giercksky KE. FAP-α and uPA show different expression patterns in premalignant and malignant esophageal lesions. Ultrastruct. Pathol.32(3), 89–96 (2008).
   PubMed Web of Science ®Google Scholar
• Nomiya T, Nemoto K, Miyachi H et al. Significance of plasminogen-activation system in the formation of macroscopic types and invasion in esophageal carcinoma. Anticancer Res.22(5), 2913–2916 (2002).
   PubMed Web of Science ®Google Scholar
• Sakakibara T, Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A. Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma. Clin. Cancer Res.10(4), 1375–1378 (2004).
   PubMedGoogle Scholar
• Tang WH, Friess H, Kekis PB et al. Serine proteinase activation in esophageal cancer. Anticancer Res.21(4A), 2249–2258 (2001).
   PubMedGoogle Scholar
• Cantero D, Friess H, Deflorin J et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br. J. Cancer75(3), 388–395 (1997).
   PubMed Web of Science ®Google Scholar
• Xue A, Scarlett CJ, Jackson CJ, Allen BJ, Smith RC. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Pancreas36(2), 160–167 (2008).
   PubMed Web of Science ®Google Scholar
• Shin SJ, Kim KO, Kim MK et al. Expression of E-cadherin and uPA and their association with the prognosis of pancreatic cancer. Jpn. J. Clin. Oncol.35(6), 342–348 (2005).
   PubMedGoogle Scholar
• Warnecke-Eberz U, Prenzel KL, Baldus SE et al. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer. Pancreas36(2), 173–177 (2008).
   PubMedGoogle Scholar
• He Y, Liu XD, Chen ZY et al. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR–uPA–MMP-2 cascade in pancreatic cancer metastasis. Clin. Cancer Res.13(11), 3115–3124 (2007).
   PubMed Web of Science ®Google Scholar
• Oka T, Ishida T, Nishino T, Sugimachi K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res.51(13), 3522–3525 (1991).
   PubMed Web of Science ®Google Scholar
• Hofmann HS, Bartling B, Simm A et al. Identification and classification of differentially expressed genes in non-small cell lung cancer by expression profiling on a global human 59.620-element oligonucleotide array. Oncol. Rep.16(3), 587–595 (2006).
   PubMed Web of Science ®Google Scholar
• Volm M, Mattern J, Koomagi R. Relationship of urokinase and urokinase receptor in non-small cell lung cancer to proliferation, angiogenesis, metastasis and patient survival. Oncol. Rep.6(3), 611–615 (1999).
   PubMedGoogle Scholar
• Salden M, Splinter TA, Peters HA et al. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Annal. Oncol.11(3), 327–332 (2000).
   PubMedGoogle Scholar
• Pedersen H, Grondahl-Hansen J, Francis D et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res.54(1), 120–123 (1994).
   PubMed Web of Science ®Google Scholar
• Offersen BV, Pfeiffer P, Andreasen P, Overgaard J. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer56(1), 43–50 (2007).
   PubMed Web of Science ®Google Scholar
• Werle B, Kotzsch M, Lah TT et al. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res.24(6), 4147–4161 (2004).
   PubMed Web of Science ®Google Scholar
• Pedersen H, Brunner N, Francis D et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res.54(17), 4671–4675 (1994).
   PubMed Web of Science ®Google Scholar
• Zekanowska E, Cieslinski K, Rosc D. Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer. Pneumonol. Alergol. Pol.72(9–10), 409–414 (2004).
   PubMedGoogle Scholar
• Pavey SJ, Marsh NA, Ray MJ, Butler D, Dare AJ, Hawson GA. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer. Boll. Soc. Ital. Biol. Sper.72(11–12), 331–340 (1996).
   PubMedGoogle Scholar
• Pappot H, Pedersen AN, Brunner N, Christensen IJ. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis. Lung Cancer51(2), 193–200 (2006).
   PubMedGoogle Scholar
• di Bernardo MC, Matakidou A, Eisen T, Houlston RS. Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis. Lung Cancer65(2), 237–241 (2009).
   PubMedGoogle Scholar
• Shi Z, Stack MS. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity. Biochem. J.407(2), 153–159 (2007).
   PubMedGoogle Scholar
• Baker EA, Leaper DJ, Hayter JP, Dickenson AJ. Plasminogen activator system in oral squamous cell carcinoma. Br. J. Oral Maxillofac. Surg.45(8), 623–627 (2007).
   PubMedGoogle Scholar
• Nozaki S, Endo Y, Kawashiri S et al. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis. Oral Oncol.34(1), 58–62 (1998).
   PubMedGoogle Scholar
• Nagata M, Fujita H, Ida H et al. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int. J. Cancer106(5), 683–689 (2003).
   PubMed Web of Science ®Google Scholar
• Hundsdorfer B, Zeilhofer Hf, Bock KP et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity – clinical relevance and prognostic value. J. Craniomaxillofac. Surg.33(3), 191–196 (2005).
   PubMedGoogle Scholar
• Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. Eur. J. Cancer34(8), 1193–1197 (1998).
   PubMedGoogle Scholar
• Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck. Anticancer Res.20(5C), 3975–3981 (2000).
   PubMedGoogle Scholar
• Speleman L, Kerrebijn JD, Look MP, Meeuwis CA, Foekens JA, Berns EM. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma. Head Neck29(4), 341–350 (2007).
   PubMedGoogle Scholar
• Naka T, Kuester D, Boltze C et al. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Hum. Pathol.39(2), 217–223 (2008).
   PubMedGoogle Scholar
• Chu QD, Hurd Tc, Harvey S et al. Overexpression of urinary plasminogen activator (uPA) protein and mRNA in thyroid carcinogenesis. Diagn. Mol. Pathol.13(4), 241–246 (2004).
   PubMedGoogle Scholar
• Horvatic Herceg G, Herceg D, Kralik M, Bence-Zigman Z, Tomic-Brzac H, Kulic A. Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study. Wien. Klin. Wochenschr.118(19–20), 601–609 (2006).
   PubMedGoogle Scholar
• Ulisse S, Baldini E, Toller M et al. Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. Eur. J. Cancer42(15), 2631–2638 (2006).
   PubMedGoogle Scholar
• Zhou L, Hayashi Y, Itoh T, Wang W, Rui J, Itoh H. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma. Pathology Int.50(5), 392–397 (2000).
   PubMedGoogle Scholar
• Itoh T, Hayashi Y, Kanamaru T et al. Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J. Gastroenterol. Hepatol.15(4), 422–430 (2000).
   PubMedGoogle Scholar
• de Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res.58(10), 2234–2239 (1998).
   PubMed Web of Science ®Google Scholar
• Tavian D, de Petro G, Benetti A, Portolani N, Giulini SM, Barlati S: u-PA and c-met mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int. J. Cancer87(5), 644–649 (2000).
   PubMed Web of Science ®Google Scholar
• Zheng Q, Tang Zy, Xue Q, Shi DR, Song HY, Tang HB. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J. Cancer Res. Clin. Oncol.126(11), 641–646 (2000).
   PubMedGoogle Scholar
• Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects. Hepatobiliary Pancreat. Dis. Int.1(1), 35–41 (2002).
   PubMedGoogle Scholar
• Zhou Q, Liang LJ, Peng BG, Zhen YY. Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients. Chin. J. Cancer25(11), 1433–1438 (2006).
   Google Scholar
• Bindal AK, Hammoud M, Shi WM, Wu SZ, Sawaya R, Rao JS. Prognostic significance of proteolytic enzymes in human brain tumors. J. Neuro-Oncol.22(2), 101–110 (1994).
   PubMedGoogle Scholar
• Caccamo DV, Keohane ME, Mckeever PE. Plasminogen activators and inhibitors in gliomas: an immunohistochemical study. Mod. Pathol.7(1), 99–104 (1994).
   PubMedGoogle Scholar
• Landau BJ, Kwaan HC, Verrusio EN, Brem SS. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res.54(4), 1105–1108 (1994).
   PubMed Web of Science ®Google Scholar
• Arai Y, Kubota T, Nakagawa T, Kabuto M, Sato K, Kobayashi H. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours. Acta Neurochir.140(4), 377–385 (1998).
   PubMedGoogle Scholar
• Levicar N, Nuttall RK, Lah TT. Proteases in brain tumour progression. Acta Neurochir.145(9), 825–838 (2003).
   PubMed Web of Science ®Google Scholar
• Salmaggi A, Croci D, Prina P et al. Production and post-surgical modification of VEGF, tPA and PAI-1 in patients with glioma. Cancer Biol. Ther.5(2), 204–209 (2006).
   PubMed Web of Science ®Google Scholar
• Kono S, Rao JS, Bruner JM, Sawaya R. Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J. Neuropathol. Exp. Neurol.53(3), 256–262 (1994).
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Johansson M, Sandstrom J, Bergenheim AT, Henriksson R. Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression. Int. J. Dev. Neurosci.17(5–6), 473–481 (1999).
   PubMedGoogle Scholar
• Le DM, Besson A, Fogg DK et al. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J. Neurosci.23(10), 4034–4043 (2003).
   PubMed Web of Science ®Google Scholar
• Hsu DW, Efird JT, Hedley-Whyte ET. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am. J. Pathol.147(1), 114–123 (1995).
   PubMedGoogle Scholar
• Oh JW, Olman M, Benveniste EN. CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells. Biol. Pharm. Bull.32(4), 573–577 (2009).
   PubMedGoogle Scholar
• Iwadate Y, Hayama M, Adachi A et al. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Res.28(1B), 415–418 (2008).
   PubMedGoogle Scholar
• Muracciole X, Romain S, Dufour H et al. PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification. Int. J. Radiat. Oncol. Biol. Phys.52(3), 592–598 (2002).
   PubMed Web of Science ®Google Scholar
• Stabuc B, Markovic J, Bartenjev I, Vrhovec I, Medved U, Kocijancic B. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma. Oncol. Rep.10(3), 635–639 (2003).
   PubMedGoogle Scholar
• de Vries TJ, Mooy CM, van Balken MR et al. Components of the plasminogen activation system in uveal melanoma – a clinico-pathological study. J. Pathol.175(1), 59–67 (1995).
   PubMed Web of Science ®Google Scholar
• Gershtein ES, Medvedeva SV, Babkina IV, Kushlinskii NE, Trapeznikov NN. Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms. Bull. Exp. Biol. Med.132(1), 670–674 (2001).
   PubMedGoogle Scholar
• Ferrier CM, de Witte HH, Straatman H et al. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. Br. J. Cancer79(9–10), 1534–1541 (1999).
   PubMed Web of Science ®Google Scholar
• Hanekom GS, Stubbings HM, Kidson SH. The active fraction of plasmatic plasminogen activator inhibitor type 1 as a possible indicator of increased risk for metastatic melanoma. Cancer Detect. Prev.26(1), 50–59 (2002).
   PubMedGoogle Scholar
• Choong PF, Ferno M, Akerman M et al. Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas. Int. J. Cancer69(4), 268–272 (1996).
   PubMed Web of Science ®Google Scholar
• Benassi MS, Ponticelli F, Azzoni E et al. Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas. Histol. Histopathol.22(9), 1017–1024 (2007).
   PubMedGoogle Scholar
• Kushlinskii NE, Yusifov AI, Gershtein ES, Solov’ev YN, Trapeznikov NN. Plasminogen activators and their inhibitor in bone tumors and tumor-like damages. Bull. Exp. Biol. Med.132(2), 780–782 (2001).
   PubMedGoogle Scholar
• Hakel C, Ueda Y, Tsuchya H, Herrera A, Blasius S, Roessner A. Plasminogen activators and their inhibitor in osteosarcomas and other bone tumors. Zentralbl. Pathol.140(4–5), 363–369 (1994).
   PubMedGoogle Scholar
• Hackel C, Czerniak B, Ayala AG, Radig K, Roessner A. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma. Cancer79(1), 53–58 (1997).
   PubMed Web of Science ®Google Scholar
• Thewes M, Elsner E, Wessner D, Engst R, Ring J. The urokinase plasminogen activator system in angiosarcoma, Kaposi’s sarcoma, granuloma pyogenicum, and angioma: an immunohistochemical study Int. J. Dermatol.39(3), 188–191 (2000).
   PubMedGoogle Scholar
• Morii T, Yabe H, Morioka H, Yamada R, Nakagawa T, Toyama Y. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma. Anticancer Res.20(5A), 3031–3036 (2000).
   PubMedGoogle Scholar
• Taubert H, Wurl P, Greither T et al. Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. Br. J. Cancer102(4), 731–737 (2010).
   PubMedGoogle Scholar
• Sheng S. The feasibility of uPA/uPAR-targeting strategies in cancer treatment. Cancer Biol. Ther.7(5), 660–662 (2008).
   PubMed Web of Science ®Google Scholar
• Ulisse S, Baldini E, Sorrenti S, D’Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr. Cancer Drug Targets9(1), 32–71 (2009).
   PubMed Web of Science ®Google Scholar
• Gondi CS, Rao JS. Therapeutic potential of siRNA-mediated targeting of urokinase plasminogen activator, its receptor, and matrix metalloproteinases. Methods Mol. Biol.487, 267–281 (2009).
   PubMedGoogle Scholar
• Oh SH, Lee OH, Schroeder CP et al. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol. Cancer Ther.5(11), 2685–2695 (2006).
   PubMed Web of Science ®Google Scholar
• Salvi A, Arici B, Alghisi A, Barlati S, de Petro G. RNA interference against urokinase in hepatocellular carcinoma xenografts in nude mice. Tumour Biol.28(1), 16–26 (2007).
   PubMedGoogle Scholar
• Subramanian R, Gondi CS, Lakka SS, Jutla A, Rao JS. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int. J. Oncol.28(4), 831–839 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou H, Tang Y, Liang X et al. RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo. Int. J. Cancer125(2), 453–462 (2009).
   PubMedGoogle Scholar
• Meryet-Figuieres M, Resina S, Lavigne C, Barlovatz-Meimon G, Lebleu B, Thierry AR. Inhibition of PAI-1 expression in breast cancer carcinoma cells by siRNA at nanomolar range. Biochimie89(10), 1228–1233 (2007).
   PubMed Web of Science ®Google Scholar
• Blake CM, Sullenger BA, Lawrence DA, Fortenberry YM. Antimetastatic potential of PAI-1-specific RNA aptamers. Oligonucleotides19(2), 117–128 (2009).
   PubMedGoogle Scholar
• Sgier D, Zuberbuehler K, Pfaffen S, Neri D. Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA. Protein Eng. Des. Sel.23(4), 261–269 (2010).
   PubMed Web of Science ®Google Scholar
• Mondino A, Blasi F: uPA and uPAR in fibrinolysis, immunity and pathology. Trend. Immunol.25(8), 450–455 (2004).
   PubMed Web of Science ®Google Scholar
• Blasi F, Carmeliet P: uPAR: a versatile signalling orchestrator. Nat. Rev. Mol Cell Biol.3(12), 932–943 (2002).
   PubMed Web of Science ®Google Scholar
• Preissner KT, Kanse SM, May AE. Urokinase receptor: a molecular organizer in cellular communication. Curr. Opin. Cell Biol.12(5), 621–628 (2000).
   PubMedGoogle Scholar
• Schmitt M, Wilhelm OG, Reuning U et al. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis Proteolysis14, 114–132 (2000).
   Google Scholar
• Lund IK, Jogi A, Rono B et al. Antibody-mediated targeting of the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis in vivo. J. Biol. Chem.283(47), 32506–32515 (2008).
   PubMed Web of Science ®Google Scholar
• Blouse GE, Botkjaer KA, Deryugina E et al. A novel mode of intervention with serine protease activity: targeting zymogen activation. J. Biol. Chem.284(7), 4647–4657 (2009).
   PubMed Web of Science ®Google Scholar
• Bialas A, Kafarski P. Proteases as anti-cancer targets – molecular and biological basis for development of inhibitor-like drugs against cancer. Anticancer Agents Med. Chem.9(7), 728–762 (2009).
   PubMedGoogle Scholar
• Muehlenweg B, Sperl S, Magdolen V, Schmitt M, Harbeck N. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert Opin. Biol. Ther.1(4), 683–691 (2001).
   PubMed Web of Science ®Google Scholar
• Setyono-Han B, Sturzebecher J, Schmalix WA et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb. Haemost.93(4), 779–786 (2005).
   PubMed Web of Science ®Google Scholar
• Killeen SD, Andrews EJ, Wang JH et al. Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, WXC-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases. Br. J. Cancer96(2), 262–268 (2007).
   PubMedGoogle Scholar
• Moiseeva EP, Almeida GM, Jones GD, Manson MM. Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol. Cancer Ther.6(11), 3071–3079 (2007).
   PubMed Web of Science ®Google Scholar
• Chen PN, Chu SC, Chiou HL, Kuo WH, Chiang CL, Hsieh YS. Mulberry anthocyanins, cyanidin 3-rutinoside and cyanidin 3-glucoside, exhibited an inhibitory effect on the migration and invasion of a human lung cancer cell line. Cancer Lett.235(2), 248–259 (2006).
   PubMed Web of Science ®Google Scholar
• Chen PN, Kuo WH, Chiang CL, Chiou HL, Hsieh YS, Chu SC. Black rice anthocyanins inhibit cancer cells invasion via repressions of MMPs and u-PA expression. Chem. Biol. Interact.163(3), 218–229 (2006).
   PubMed Web of Science ®Google Scholar
• Lamy S, Lafleur R, Bedard V et al. Anthocyanidins inhibit migration of glioblastoma cells: structure–activity relationship and involvement of the plasminolytic system. J. Cell. Biochem.100(1), 100–111 (2007).
   PubMed Web of Science ®Google Scholar
• Valachovicova T, Slivova V, Bergman H, Shuherk J, Sliva D. Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-κaB/AP-1-dependent and -independent pathways. Int. J. Oncol.25(5), 1389–1395 (2004).
   PubMed Web of Science ®Google Scholar
• Iguchi K, Tatsuda Y, Usui S, Hirano K. Pamidronate down-regulates urokinase-type plasminogen activator expression in PC-3 prostate cancer cells. Anticancer Res.27(6B), 3843–3848 (2007).
   PubMedGoogle Scholar
• Slivova V, Zaloga G, Demichele SJ et al. Green tea polyphenols modulate secretion of urokinase plasminogen activator (uPA) and inhibit invasive behavior of breast cancer cells. Nutr. Cancer52(1), 66–73 (2005).
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Suzuki M, Kanayama N, Terao T. A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation. Clin. Exp. Metastasis21(2), 159–166 (2004).
   PubMed Web of Science ®Google Scholar
• Andrews HN, Habibi G, Kucab JE, Dunn SE. Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells. Breast Cancer Res. and Treatment94(1), 47–52 (2005).
   PubMedGoogle Scholar
• Ishikawa H, Satoh H, Kamma H et al. The effect of TNP-470 on cell proliferation and urokinase-type plasminogen activator and its inhibitor in human lung cancer cell lines. J. Exp. Ther. Oncol.1(6), 390–396 (1996).
   PubMedGoogle Scholar
• Carriero MV, Longanesi-Cattani I, Bifulco K et al. Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis. Mol. Cancer Ther.8(9), 2708–2717 (2009).
   PubMedGoogle Scholar
• Ippoliti R, Lendaro E, Benedetti PA et al. Endocytosis of a chimera between human pro-urokinase and the plant toxin saporin: an unusual internalization mechanism. FASEB J.14(10), 1335–1344 (2000).
   PubMedGoogle Scholar
• Sun Q, Xu Q, Dong X et al. A hybrid protein comprising atf domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy. Int. J. Cancer123(4), 942–950 (2008).
   PubMed Web of Science ®Google Scholar
• Hu XW, Duan HF, Gao LH et al. Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. Cancer Biol. Ther.7(5), 651–659 (2008).
   PubMed Web of Science ®Google Scholar
• Jing Y, Tong C, Zhang J et al. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Cancer Res.69(4), 1459–1468 (2009).
   PubMed Web of Science ®Google Scholar
• Abi-Habib Rj, Singh R, Liu S, Bugge TH, Leppla SH, Frankel AE. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Mol. Cancer Ther.5(10), 2556–2562 (2006).
   PubMed Web of Science ®Google Scholar
• Rono B, Romer J, Liu S, Bugge TH, Leppla SH, Kristjansen PE. Antitumor efficacy of a urokinase activation-dependent anthrax toxin. Mol. Cancer Ther.5(1), 89–96 (2006).
   PubMed Web of Science ®Google Scholar
• Su Y, Ortiz J, Liu S et al. Systematic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice. Cancer Res.67(7), 3329–3336 (2007).
   PubMedGoogle Scholar
• Goldstein LJ. Experience in Phase I trials and an upcoming Phase II study with uPA inhibitors in metastatic breast cancer. Breast Care3(Suppl. 2), 25–28 (2008).
   PubMed Web of Science ®Google Scholar
• Meyer JE, Brocks C, Graefe H et al. The oral serine protease inhibitor WX-671 – a safe and effective drug against metastatic spread in patients with advanced head and neck carcinoma. Breast Care3(Suppl. 2), 20–24 (2008).
   PubMed Web of Science ®Google Scholar
• Ghamande SA, Silverman MH, Huh W et al. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol. Oncol.111(1), 89–94 (2008).
   PubMed Web of Science ®Google Scholar
• Berkenblit A, Matulonis UA, Kroener JF et al. A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a Phase I trial. Gynecol. Oncol.99(1), 50–57 (2005).
   PubMed Web of Science ®Google Scholar
• Binder BR, Mihaly J. The plasminogen activator inhibitor “Paradox” in cancer. Immunol. Lett.118(2), 116–124 (2008).
   PubMed Web of Science ®Google Scholar
• Bajou K, Noel A, Gerard Rd et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med.4(8), 923–928 (1998).
   PubMed Web of Science ®Google Scholar
• Romer Mu, Larsen L, Offenberg H, Brunner N, Lademann UA. Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/AKT cell survival pathway. Neoplasia10(10), 1083–1091 (2008).
   PubMedGoogle Scholar
• Kwaan HC, Wang J, Svoboda K, Declerck PJ. Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br. J. Cancer82(10), 1702–1708 (2000).
   PubMed Web of Science ®Google Scholar
• Dupont DM, Madsen JB, Kristensen T et al. Biochemical properties of plasminogen activator inhibitor-1. Front. Biosci.14, 1337–1361 (2009).
   Google Scholar
• Madsen JB, Dupont DM, Andersen TB et al. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1. Biochemistry49(19), 4103–4115 (2010).
   PubMed Web of Science ®Google Scholar
• Rupin A, Gaertner R, Mennecier P et al. S35225 is a direct inhibitor of plasminogen activator inhibitor type-1 activity in the blood. Thromb. Res.122(2), 265–270 (2008).
   PubMed Web of Science ®Google Scholar
• Izuhara Y, Takahashi S, Nangaku M et al. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler. Thromb. Vasc. Biol.28(4), 672–677 (2008).
   PubMed Web of Science ®Google Scholar
• Mathiasen L, Dupont DM, Christensen A et al. A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. Mol. Pharmacol.74(3), 641–653 (2008).
   PubMedGoogle Scholar
• Hennan JK, Elokdah H, Leal M et al. Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis. J. Pharmacol. Exp. Ther.314(2), 710–716 (2005).
   PubMed Web of Science ®Google Scholar
• Leik CE, Su EJ, Nambi P, Crandall Dl, Lawrence DA. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J. Thromb. Haemost.4(12), 2710–2715 (2006).
   PubMed Web of Science ®Google Scholar
• Harbeck N, Kates RE, Look MP et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3424). Cancer Res.62(16), 4617–4622 (2002).
   PubMed Web of Science ®Google Scholar
• Wurtz SO, Schrohl AS, Mouridsen H, Brunner N. TIMP-1 as a tumor marker in breast cancer – an update. Acta Oncol.47(4), 580–590 (2008).
   PubMed Web of Science ®Google Scholar
• Innocenti F, Schilsky Rl. Translating the cancer genome into clinically useful tools and strategies. Dis. Model Mech.2(9–10), 426–429 (2009).
   PubMed Web of Science ®Google Scholar
• Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst.101(21), 1446–1452 (2009).
   PubMed Web of Science ®Google Scholar
• Tan DS, Thomas GV, Garrett MD et al. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J.15(5), 406–420 (2009).
   PubMed Web of Science ®Google Scholar
• Jensen EV, Jacobson HI, Walf AA, Frye CA. Estrogen action: a historic perspective on the implications of considering alternative approaches. Physiol. Behav.99(2), 151–162 (2010).
   PubMed Web of Science ®Google Scholar
• Andreasen PA. PAI-1 – a potential therapeutic target in cancer. Curr. Drug Targets8(9), 1030–1041 (2007).
   PubMed Web of Science ®Google Scholar
• Sperl S, Mueller MM, Wilhelm OG, Schmitt M, Magdolen V, Moroder L. The uPA/uPA receptor system as a target for tumor therapy. Drug News Perspect.14(7), 401–411 (2001).
   PubMed Web of Science ®Google Scholar
• Heinemann V, Ebert MP, Pinter T, Bevan P, Neville NG, Mala C. Randomized Phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer. J. Clin. Oncol.28, 15s (2010) (Abstract 4060).
   PubMed Web of Science ®Google Scholar
• Goldstein LJ, Stemmer SM, Schmalfeldt B et al. Phase II, two-arm, double-blind, multicenter, randomized study of the combination of oral WX-671 plus capecitabine versus capecitabine in first-line HER2-negative metastatic breast cancer (MBC). J. Clin. Oncol.28, 15s (2010) (Abstract TPS131).
   PubMed Web of Science ®Google Scholar
• Mengele K, Napieralski R, Magdolen V et al. Characteristics of the level-of–evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev. Mol. Diagn.10(7) 947–962 (2010).
   PubMed Web of Science ®Google Scholar